Morrow is now devoting his life to prostate cancer advocacy and urging other younger, high-risk men to get screened early. He ...
Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...
MedPage Today on MSN
Practice-Influencing Results in Oligometastatic Prostate Cancer
Median progression-free survival (PFS) increased from 7.4 months with stereotactic body radiotherapy (SBRT) to 17.6 months with the addition of 177 lutetium (Lu) PNT2002 targeting prostate-specific ...
News-Medical.Net on MSN
Combining radiopharmaceuticals with targeted radiation improves progression-free survival in prostate cancer patients
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived ...
Art Imaging By Trish Yerges for Grande Ronde Hospital September is Prostate Cancer Awareness Month—a reminder that men age 50 ...
4don MSN
Telix Pharmaceuticals (TLX) Limited Receives Transitional Pass-Through payment status for Gozellix
The Transitional Pass-Through payment status means that hospitals will get separate reimbursement for using Gozellix starting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback